Merck stock price hits a 52-week high on Deutsche Bank upgrade as MRK heads into holiday week

Merck & Co Inc jumped 1.8% to settle at $121.41 on Friday, notching a new 52-week high of $123.33 during the session, after Deutsche Bank bumped its rating and set a $150 price target for the pharma giant. U.S. markets then closed for the weekend.

NYSE:MRK · Pharmaceutical Industry · Stock Market
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

• Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in early February.
29 January 2026
····
GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

GSK announced that the European Commission has greenlit its RSV vaccine Arexvy for adults 18 and older, expanding eligibility beyond those 60-plus and high-risk individuals aged 50 to 59. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, GSK’s head of Vaccines and Infectious Diseases R&D. The approval applies across EU member states and countries in the European Economic Area. GSK pointed to an average of 158,000 RSV-related adult hospitalisations annually within the EU.
26 January 2026
··
1 2 3 4 5 … 10
Follow on Google News
Add as preferred source Open in Google News